This “Steroid Refractory Acute Graft-Versus-Host Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 9+ companies and 9+ pipeline drugs in Steroid Refractory Acute Graft-Versus-Host Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Steroid Refractory Acute Graft-Versus-Host Disease Understanding
Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (alloHCT). aGVHD occurs primarily in the skin, gastrointestinal tract, and liver and can occur in alloHCT recipients despite prophylaxis. Systemic steroid therapy is the first-line treatment for aGVHD. However, in approximately 35-50% of patients, aGVHD becomes refractory to systemic steroid therapy. aGVHD is diagnosed clinically after laboratory analysis, imaging, and/or endoscopic examination to exclude potential differential diagnoses. Mortality is high and quality of life is poor in these patients, and only treatment is currently approved therapy for steroid-refractory aGVHD (SR-aGVHD).
"Steroid Refractory Acute Graft-Versus-Host Disease - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Steroid Refractory Acute Graft-Versus-Host Disease pipeline landscape is provided which includes the disease overview and Steroid Refractory Acute Graft-Versus-Host Disease treatment guidelines. The assessment part of the report embraces, in depth Steroid Refractory Acute Graft-Versus-Host Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Steroid Refractory Acute Graft-Versus-Host Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Steroid Refractory Acute Graft-Versus-Host Disease R&D. The therapies under development are focused on novel approaches to treat/improve Steroid Refractory Acute Graft-Versus-Host Disease.
This segment of the Steroid Refractory Acute Graft-Versus-Host Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Neihulizumab (AbGn-168H) is a humanized, immune checkpoint agonistic antibody with a mechanism of action, which preferentially induces apoptosis of late-stage activated T cells. This novel activated-T cell apoptosis-inducing antibody effectively eliminates chronic pathogenic T cells while fully maintaining host defense. The drug is in Phase II clinical studies for the treatment of psoriatic arthritis, ulcerative colitis and in Phase I clinical studies to treat steroid-refractory acute GvHD after allogeneic hematopoietic cell transplantation (HCT).
MaaT013 is a full-ecosystem, off-the-shelf, standardized, pooled-donor, high-richness microbiome biotherapeutic in enema formulation. The drug is in Phase III clinical development studies for the treatment of patients with steroids and ruxolitinib-resistant aGVHD.
This segment of the report provides insights about the different Steroid Refractory Acute Graft-Versus-Host Disease drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 9+ key companies which are developing the therapies for Steroid Refractory Acute Graft-Versus-Host Disease. The companies which have their Steroid Refractory Acute Graft-Versus-Host Disease drug candidates in the most advanced stage, i.e. Preregistration include, ElsaLys Biotech.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Steroid Refractory Acute Graft-Versus-Host Disease therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Steroid Refractory Acute Graft-Versus-Host Disease drugs.
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
Steroid Refractory Acute Graft-Versus-Host Disease Understanding
Steroid Refractory Acute Graft-Versus-Host Disease: Overview
Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (alloHCT). aGVHD occurs primarily in the skin, gastrointestinal tract, and liver and can occur in alloHCT recipients despite prophylaxis. Systemic steroid therapy is the first-line treatment for aGVHD. However, in approximately 35-50% of patients, aGVHD becomes refractory to systemic steroid therapy. aGVHD is diagnosed clinically after laboratory analysis, imaging, and/or endoscopic examination to exclude potential differential diagnoses. Mortality is high and quality of life is poor in these patients, and only treatment is currently approved therapy for steroid-refractory aGVHD (SR-aGVHD).
"Steroid Refractory Acute Graft-Versus-Host Disease - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Steroid Refractory Acute Graft-Versus-Host Disease pipeline landscape is provided which includes the disease overview and Steroid Refractory Acute Graft-Versus-Host Disease treatment guidelines. The assessment part of the report embraces, in depth Steroid Refractory Acute Graft-Versus-Host Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Steroid Refractory Acute Graft-Versus-Host Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Steroid Refractory Acute Graft-Versus-Host Disease R&D. The therapies under development are focused on novel approaches to treat/improve Steroid Refractory Acute Graft-Versus-Host Disease.
Steroid Refractory Acute Graft-Versus-Host Disease Emerging Drugs Chapters
This segment of the Steroid Refractory Acute Graft-Versus-Host Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Steroid Refractory Acute Graft-Versus-Host Disease Emerging Drugs
Neihulizumab: AltruBio
Neihulizumab (AbGn-168H) is a humanized, immune checkpoint agonistic antibody with a mechanism of action, which preferentially induces apoptosis of late-stage activated T cells. This novel activated-T cell apoptosis-inducing antibody effectively eliminates chronic pathogenic T cells while fully maintaining host defense. The drug is in Phase II clinical studies for the treatment of psoriatic arthritis, ulcerative colitis and in Phase I clinical studies to treat steroid-refractory acute GvHD after allogeneic hematopoietic cell transplantation (HCT).
MaaT013: MaaT Pharma
MaaT013 is a full-ecosystem, off-the-shelf, standardized, pooled-donor, high-richness microbiome biotherapeutic in enema formulation. The drug is in Phase III clinical development studies for the treatment of patients with steroids and ruxolitinib-resistant aGVHD.
Steroid Refractory Acute Graft-Versus-Host Disease: Therapeutic Assessment
This segment of the report provides insights about the different Steroid Refractory Acute Graft-Versus-Host Disease drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Steroid Refractory Acute Graft-Versus-Host Disease
There are approx. 9+ key companies which are developing the therapies for Steroid Refractory Acute Graft-Versus-Host Disease. The companies which have their Steroid Refractory Acute Graft-Versus-Host Disease drug candidates in the most advanced stage, i.e. Preregistration include, ElsaLys Biotech.
Phases
This report covers around 9+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Steroid Refractory Acute Graft-Versus-Host Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Steroid Refractory Acute Graft-Versus-Host Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Steroid Refractory Acute Graft-Versus-Host Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Steroid Refractory Acute Graft-Versus-Host Disease drugs.
Steroid Refractory Acute Graft-Versus-Host Disease Report Insights
- Steroid Refractory Acute Graft-Versus-Host Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Steroid Refractory Acute Graft-Versus-Host Disease Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Steroid Refractory Acute Graft-Versus-Host Disease drugs?
- How many Steroid Refractory Acute Graft-Versus-Host Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Steroid Refractory Acute Graft-Versus-Host Disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Steroid Refractory Acute Graft-Versus-Host Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Steroid Refractory Acute Graft-Versus-Host Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- ElsaLys Biotech
- Suzhou Zelgen Biopharmaceuticals
- Incyte Corporation
- ASC Therapeutics
- Xenikos
- Medac
- MaaT Pharma
- AltruBio
Key Products
- Jaktinib Hydrochloride Tablets
- MaaT013
- Neihulizumab
- Inolimomab
- Itacitinib
- ASC930
- T-Guard
- MC 0518
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive Summary
Steroid Refractory Acute Graft-Versus-Host Disease: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Steroid Refractory Acute Graft-Versus-Host Disease - Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
MaaT013: MaaT Pharma
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
ASC930: ASC Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
Neihulizumab: AltruBio
- Product Description
- Research and Development
- Product Development Activities
Preclinical/Discovery Stage Products
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Steroid Refractory Acute Graft-Versus-Host Disease Key Companies
Steroid Refractory Acute Graft-Versus-Host Disease Key Products
Steroid Refractory Acute Graft-Versus-Host Disease- Unmet Needs
Steroid Refractory Acute Graft-Versus-Host Disease- Market Drivers and Barriers
Steroid Refractory Acute Graft-Versus-Host Disease- Future Perspectives and Conclusion
Steroid Refractory Acute Graft-Versus-Host Disease Analyst Views
AppendixList of Tables
Table 1 Total Products for Steroid Refractory Acute Graft-Versus-Host Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Steroid Refractory Acute Graft-Versus-Host Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- ElsaLys Biotech
- Suzhou Zelgen Biopharmaceuticals
- Incyte Corporation
- ASC Therapeutics
- Xenikos
- Medac
- MaaT Pharma
- AltruBio
